Anzeige
Mehr »
Login
Sonntag, 31.05.2020 Börsentäglich über 12.000 News von 628 internationalen Medien
Silber-Aktien im Rausch! Diese Silber-Granate steht vor massiver Neubewertung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XA8R ISIN: DK0060534915 Ticker-Symbol: NOVC 
Tradegate
29.05.20
21:50 Uhr
59,20 Euro
+0,43
+0,73 %
1-Jahres-Chart
NOVO NORDISK A/S Chart 1 Jahr
5-Tage-Chart
NOVO NORDISK A/S 5-Tage-Chart
RealtimeGeldBriefZeit
59,4159,6030.05.
59,4159,6029.05.
GlobeNewswire (Europe)
721 Leser
Artikel bewerten:
(2)

Novo Nordisk A/S: Rybelsus (oral semaglutide) approved for the treatment of adults with type 2 diabetes in the EU

Bagsværd, Denmark, 4 April 2020 - Novo Nordisk today announced that the European Commission (EC) has granted marketing authorisation for Rybelsus (oral semaglutide), for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycaemic control as an adjunct to diet and exercise. The marketing authorisation applies to all 27 European Union member states and the United Kingdom.

Rybelsus is the first and only oral glucagon-like-peptide-1 (GLP-1) receptor agonist. The approval is based on the results from 10 PIONEER clinical trials, in which Rybelsus after 52 weeks demonstrated statistically significant reductions in HbA1c vs sitagliptin, empagliflozin and liraglutide and with up to 4.3 kg weight reduction. Across the PIONEER programme, Rybelsus demonstrated a safe and well-tolerated profile, with the most common adverse event being mild to moderate nausea which diminished over time.

"We are very excited about the approval of Rybelsus as we can now offer people in Europe living with type 2 diabetes the first and only GLP-1 in a tablet," said Mads Krogsgaard Thomsen, executive vice president and chief science officer. "Based on its strong clinical profile, we believe Rybelsus has the potential to set a new standard for the treatment of type 2 diabetes, as millions of people are currently not achieving target blood sugar levels on available oral antidiabetic medications."

The launch of Rybelsus is expected to take place in the first EU countries in the second half of 2020.

About Rybelsus

Rybelsus (oral semaglutide) is an analogue of the naturally occurring hormone GLP-1. Rybelsus is approved in the US, Switzerland and EU as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is administered once daily and is approved for use in two therapeutic dosages, 7 mg and 14 mg.

Rybelsus is currently under review by several regulatory agencies, including the Japanese Pharmaceuticals and Medical Devices Agency.

Further information

Media:
Mette Kruse Danielsen+45 3079 3883mkd@novonordisk.com (mailto:mkd@novonordisk.com)
Ken Inchausti (US)+1 609 240 9429kiau@novonordisk.com (mailto:kiau@novonordisk.com)
Investors:
Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com (mailto:dabo@novonordisk.com)
Valdemar Borum Svarrer+45 3079 0301jvls@novonordisk.com (mailto:jvls@novonordisk.com)
Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com (mailto:arnd@novonordisk.com)
Mark Joseph Root+45 3079 4211mjhr@novonordisk.com (mailto:mjhr@novonordisk.com)
Kristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com (mailto:krdb@novonordisk.com)

Company announcement No 21 / 2020

Attachment

  • PR200404_Rybelsus_approval_EU (https://ml-eu.globenewswire.com/Resource/Download/4a61f1c9-f8ce-4d0d-a063-14cc4f66e465)
NOVO NORDISK-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2020 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.